Prevention of Alzheimer disease

Alzheimer Disease and Associated Disorders

Volumn 20, Issue SUPPL. 2, 2006, Pages

  Thal, Leon J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Disease progression; Primary prevention; Treatment

Indexed keywords

ALPHA TOCOPHEROL; ANTIHYPERTENSIVE AGENT; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA CAROTENE; CALCIUM CHANNEL BLOCKING AGENT; CELECOXIB; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ESTROGEN; GESTAGEN; GINKGO BILOBA EXTRACT; NAPROXEN; NITRENDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SELENIUM;

ALZHEIMER DISEASE; COGNITION; DISEASE COURSE; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HUMAN; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SAMPLING; UNSPECIFIED SIDE EFFECT;

ALZHEIMER DISEASE; HUMANS; PRIMARY PREVENTION;

EID: 33747592124     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002093-200607001-00015     Document Type: Review

References (15)

1. Ernst RL, Hay JW. The US economic and social costs of Alzheimer's disease revisited. Am J Public Health. 1994;84:1261-1264.
2. Katzman R, Fox PJ. The world-wide impact of dementia. Projections of prevalence and costs. In: Mayeux R, Christen Y, eds. Epidemiology of Alzheimer's Disease: From Gene to Prevention. New York: Springer-Verlag; 1999:1-17.
3. Bill and Melinda Gates Foundation. Available at: http://www. gatesfoundation.org/default.htm. Accessed May 15, 2006.
4. Bachman DL, Wolf PA, Linn RT, et al. Incidence of dementia and probable Alzheimer's disease in a general population: the Framingham study. Neurology. 1993;43:515-519.
5. Hebert LE, Scherr PA, Beckett LA. Age-specific incidence of Alzheimer's disease in a community population. JAMA. 1995;273:1354-1359.
6. Kawas C, Gray S, Brookmeyer R, et al. Age-specific incidence rates of Alzheimer's disease. The Baltimore longitudinal study of aging. Neurology. 2000;54:2072-2077.
7. Shumaker S, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women. Women's Health Initiative Memory Study. JAMA. 2003;289:2651-2652.
8. Shumaker S, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women. Women's Health Initiative Memory Study. JAMA. 2004;291:2947-2958.
9. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7-22.
10. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertensive: final results of the systolic hypertension in the elderly program. JAMA. 1991;265:3255-3264.
11. Prince MJ, Bird AS, Blizard RA, et al. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. BMJ. 1996;312:801-805.
12. Forette F, Seux M-L, Staessen J, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (syst-Eur) trial. Lancet. 1998;352:1347-1351.
13. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertension. 2003;21:875-886.
14. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet. 2001;358:1033-1041.
15. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88:1337-1342.